Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma

22 Sept 2010

Abstract excerpt

BACKGROUND: Epigenetic dysregulation is a hallmark of cancer, including multiple myeloma. Inhibitors of histone deacetylases (HDACs) induce DNA hyperacetylation by inhibiting removal of acetyl groups from amino tails on histone proteins, thereby uncoiling condensed chromatin favoring transcription of silenced genes, including tumor suppressor genes. Romidepsin is an HDAC inhibitor that exhibits antiproliferative...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Histone Deacetylase Inhibitors Research
Share to Multiple Myeloma Research and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 20862746
DOI: 10.1002/cncr.25584

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myelomaPMID 20862746Read ↗

Exploring the role of histone deacetylase and histone deacetylase inhibitors in the context of multiple myeloma: mechanisms, therapeutic implications, and future perspectivesSemantic proximity Read ↗

A phase 1 clinical trial of the repurposable acetyl-lysine mimetic, n-methyl-2-pyrrolidone (NMP), in relapsed or refractory multiple myelomaSemantic proximity Read ↗

Histone Deacetylase Inhibitor Romidepsin Has Differential Activity in Core Binding Factor Acute Myeloid LeukemiaSemantic proximity Read ↗

Romosozumab Safely Restores Bone Mass in Multiple Myeloma via Osteoblast Reprogramming: A Phase IIa StudySemantic proximity Read ↗

Romidepsin for the treatment of cutaneous T-cell lymphomaSemantic proximity Read ↗

Romidepsin (FK228) fails in counteracting the transformed phenotype of rhabdomyosarcoma cells but efficiently radiosensitizes, in vitro and in vivo, the alveolar phenotype subtype.Semantic proximity Read ↗

Plasma cell dependence on histone/protein deacetylase 11 reveals a therapeutic target in multiple myelomaSemantic proximity Read ↗

Research Progress of Protein Arginine Methyltransferases (PRMTs) in Multiple Myeloma: From Molecular Mechanisms to Targeted TherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.